Sigyn Therapeutics Expands Board with Experienced Medical Technology Investor Michael Ryan
TL;DR
Sigyn Therapeutics appointed Michael Ryan, a seasoned executive and investor, to its Board of Directors, enhancing the company's strategic expertise.
Sigyn Therapy aims to treat life-threatening infections through blood purification technologies, reducing viral pathogens, bacterial toxins, and pro-inflammatory cytokines from human blood plasma.
Sigyn Therapeutics' innovative therapies offer strategic value to the dialysis and biopharmaceutical industry, potentially extending the lives of individuals with life-threatening conditions.
Mr. Ryan's extensive industry experience and contributions to Sigyn Therapeutics introduce a compelling strategy to address global health challenges through advanced blood purification technologies.
Found this article helpful?
Share it with your network and spread the knowledge!
Sigyn Therapeutics, a developer of blood purification technologies, has strengthened its leadership team by appointing Michael Ryan to its Board of Directors. Ryan brings extensive experience in medical technology and early-stage investments to the company.
As a Founding Director of Irrus Investments, Ryan has a proven track record in the life sciences sector. The investment syndicate has invested over $50 million in 40 early-stage companies across Ireland, the UK, Sweden, and the United States.
Ryan's professional background includes serving as CEO of Sedana Medical and leading Artema Medical AB, demonstrating his strategic leadership in medical technology companies. His educational credentials include a B.Eng in Mechanical Engineering and a Masters in Industrial Engineering from University College Dublin.
Sigyn Therapeutics CEO Jim Joyce highlighted Ryan's potential contributions, noting his expertise will help the company advance its mission of developing blood purification technologies. Ryan expressed enthusiasm about joining the board, particularly citing the company's strategy to address significant global health challenges.
The company's lead product, Sigyn Therapy, shows promising capabilities in reducing viral pathogens, bacterial toxins, and pro-inflammatory cytokines from human blood plasma. The technology potentially offers treatments for life-threatening conditions such as viruses, antibiotic-resistant infections, endotoxemia, and sepsis.
Beyond its primary therapy, Sigyn Therapeutics is developing an oncology pipeline including platforms to enhance immunotherapeutic antibody delivery and reduce chemotherapy toxicity. These innovations could provide strategic value to the dialysis and biopharmaceutical industries.
Curated from NewMediaWire
